Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Medication helps quell the agitation of dementia

22.07.2004


Doctors are reporting some success in treating one of the most troubling symptoms of dementias such as Alzheimer’s disease. A drug commonly used to treat schizophrenia and other psychotic disorders appears effective at reducing actions like screaming at or slapping caregivers – agitated behaviors that occur in as many as half of patients.



The work, led by researchers at the University of Rochester Medical Center, was presented July 22 at the 9th International Conference on Alzheimer’s Disease and Related Disorders in Philadelphia, Pa. The conference is sponsored by the Alzheimer’s Association.

The medication tested in the study, quetiapine, was effective at treating agitation, but with fewer side effects than other medicines that doctors turn to now.


"One of the most stressing and vexing changes in behavior in patients with dementia is agitation, which occurs in about half of patients at some point in their illness," says Pierre Tariot, M.D., professor of Psychiatry, Medicine, and Neurology, who led the study. "This behavior can be terrifying to the family and is one of the major reasons many families end up placing their loved ones in nursing homes."

Agitation is also difficult for doctors to treat. Currently there is no medication approved by the Food & Drug Administration to treat agitation in patients with dementia, though doctors and families often try to quell the symptoms with drugs that have been approved for other uses.

Doctors try anti-psychotic medications that usually reduce incidents such as slapping or yelling at caregivers or family members in about 15 to 20 percent of patients, Tariot says. But such medications can cause side effects like weight gain, high cholesterol, sleepiness, and Parkinson’s-like movement difficulties, and some have recently been linked to higher incidences of cerebrovascular "adverse events" such as strokes and transient ischemic attacks.

"All the drugs used currently, including quetiapine, have drawbacks," says Tariot, who is also a researcher in the university’s Center for Aging and Developmental Biology. "There is no ideal solution. For each patient you have to weigh the benefit of the drug against the potential cost in terms of side effects."

Tariot helped lead the study of quetiapine, a newer type of medication known as an "atypical antipsychotic." In a 10-week study of 333 people in nursing homes, the medication reduced such behaviors about 20 percent more often than a placebo did, comparable to the other drugs now available. In addition, the behavior of patients on the medication was more likely to be rated as "improved" or "very much improved," compared to other patients not on the medicine, by doctors and nurses who did not know which patients were on the medicine and which were not.

Significantly, in Tariot’s study and in another presented at the meeting by Lon Schneider, M.D., of the University of Southern California, the medication has shown no evidence so far of causing serious side effects such as strokes, although it does cause sleepiness in some people.

"Quetiapine appears to show a similar treatment effect as other medications commonly used to treat agitation, but with a side effect profile that may be different from the other agents," says Tariot, who also serves as a paid consultant to AstraZeneca, which makes Seroquel®, the brand name of quetiapine. "If quetiapine remains free of the most worrisome side effects through further studies, that would represent an advantage and would offer a new therapeutic option for patients and their families."

While experienced clinicians often turn to atypical antipsychotics like quetiapine to treat agitation in dementia patients, Tariot says this is the first large, double-blind, placebo-controlled study to evaluate just how well quetiapine works. More information is expected next year, when results are announced from a large study funded by the National Institutes of Health that is the first to compare several atypical antipsychotics – such as quetiapine, risperidone, and olanzapine – for treating Alzheimer’s and schizophrenia.

Before turning to medications, however, Tariot and other experts say the best way to treat dementia patients who are agitated is to try to understand if there is a reason underlying the behavior. Health care workers should make sure the person isn’t in pain, for instance, and that caregiver behavior is appropriate and respectful. Check to see that there aren’t features in the environment that can be easily changed, such as excessive heat or noise, which may be disturbing the patient. Sometimes, distracting a patient or changing the subject, as a parent does with a young child, is helpful. Sometimes other medications used to treat Alzheimer’s disease, such as cholinesterase inhibitors or memantine, can alleviate these behaviors. When all such efforts fail – which they do often in patients with dementia, Tariot says – doctors and families should consider medication.

"It’s clear that Alzheimer’s will be the pandemic of the West in the next century," Tariot says. "Right now there are approximately 4.5 million Americans with dementia, and that number is expected to triple over the next few decades. Many of these patients will experience significant change in their emotions and personality. It’s imperative that we find better treatments as soon as possible."

Tom Rickey | EurekAlert!
Further information:
http://www.urmc.rochester.edu

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>